Ability Pharmaceuticals, SL

Ability Pharmaceuticals, SL is rated 3 out of 5 in the category biotechnology. Read and write reviews about Ability Pharmaceuticals, SL. AbilityPharma (www.abilitypharma.com) is a clinical-stage biopharmaceutical company committed to develop first-in-class therapies that address unmet medical needs in the oncology space. ABTL0812, the most advanced asset, is a drug candidate in phase 2 clinical trials as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin. ABTL0812 is a first-in-class oral anticancer compound causing cell death through autophagy by inhibiting the PI3K/Akt/mTOR pathway. It induces the overexpression of TRIB3, an endogenous negative regulator of Akt. Its unique mechanism of action was published at Clinical Cancer Research in December 2015. The product has potential in several cancer types as first-line and maintenance therapy including lung, endometrial, pancreatic, breast, head and neck cancer, glioblastoma, cholangiocarcinoma and the pediatric cancer neuroblastoma. Orphan Drug Designation for neuroblastoma and pancreatic cancer was granted by US FDA and Europe EMA. ODD application planned for cholangiocarcinoma. Development and marketing rights for Greater China granted to SciClone Pharmaceuticals, Inc. in a territorial license agreement were signed in April 2016.